Analyst Price Targets — DARE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 24, 2024 7:45 am | Douglas Tsao | H.C. Wainwright | $12.00 | $3.50 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Dare Bioscience (DARE) |
Latest News for DARE
Daré Bioscience, Inc. (DARE) Q4 2025 Earnings Call Transcript
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.64 per share a year ago.
Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts
DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her DARE to PLAY™ Sildenafil Cream Is Rewriting the Story of Sexual Health — For Her
• Extends the budget period for the ~$2M total NIH grant funding award for DARE-PTB1 through November 2026 • DARE-PTB1 targets preterm birth, for which there are no FDA-approved treatment options • Award reflects Daré's strategy of leveraging non-dilutive grant funding to advance a deep, differentiated pipeline addressing the most persistent unmet needs in women's health
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for DARE.
U.S. House Trading
No House trades found for DARE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.